Lopinavir; Ritonavir Patent Expiration
Lopinavir; Ritonavir is used for treating HIV-1 infection in combination with other antiretroviral agents. It was first introduced by Abbvie Inc
Lopinavir; Ritonavir Patents
Given below is the list of patents protecting Lopinavir; Ritonavir, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Kaletra | US5484801 | Pharmaceutical composition for inhibiting HIV protease |
Jan 28, 2014
(Expired) | Abbvie |
| Kaletra |
US5484801 (Pediatric) | Pharmaceutical composition for inhibiting HIV protease |
Jul 28, 2014
(Expired) | Abbvie |
| Kaletra | US5541206 | Retroviral protease inhibiting compounds |
Jul 30, 2013
(Expired) | Abbvie |
| Kaletra |
US5541206 (Pediatric) | Retroviral protease inhibiting compounds |
Jan 30, 2014
(Expired) | Abbvie |
| Kaletra | US5648497 | Retroviral protease inhibiting compounds |
Jul 15, 2014
(Expired) | Abbvie |
| Kaletra |
US5648497 (Pediatric) | Retroviral protease inhibiting compounds |
Jan 15, 2015
(Expired) | Abbvie |
| Kaletra | US5886036 | Retroviral protease inhibiting compounds |
Nov 19, 2013
(Expired) | Abbvie |
| Kaletra |
US5886036 (Pediatric) | Retroviral protease inhibiting compounds |
May 19, 2014
(Expired) | Abbvie |
| Kaletra | US5914332 | Retroviral protease inhibiting compounds |
Dec 13, 2015
(Expired) | Abbvie |
| Kaletra |
US5914332 (Pediatric) | Retroviral protease inhibiting compounds |
Jun 13, 2016
(Expired) | Abbvie |
| Kaletra | US5948436 | Pharmaceutical composition |
Sep 13, 2013
(Expired) | Abbvie |
| Kaletra |
US5948436 (Pediatric) | Pharmaceutical composition |
Mar 13, 2014
(Expired) | Abbvie |
| Kaletra | US6037157 | Method for improving pharmacokinetics |
Jun 26, 2016
(Expired) | Abbvie |
| Kaletra |
US6037157 (Pediatric) | Method for improving pharmacokinetics |
Dec 26, 2016
(Expired) | Abbvie |
| Kaletra | US6232333 | Pharmaceutical composition |
Nov 07, 2017
(Expired) | Abbvie |
| Kaletra |
US6232333 (Pediatric) | Pharmaceutical composition |
May 07, 2018
(Expired) | Abbvie |
| Kaletra | US6284767 | Retroviral protease inhibiting compounds |
Feb 15, 2016
(Expired) | Abbvie |
| Kaletra |
US6284767 (Pediatric) | Retroviral protease inhibiting compounds |
Aug 15, 2016
(Expired) | Abbvie |
| Kaletra | US6458818 | Pharmaceutical composition |
Nov 07, 2017
(Expired) | Abbvie |
| Kaletra |
US6458818 (Pediatric) | Pharmaceutical composition |
May 07, 2018
(Expired) | Abbvie |
| Kaletra | US6521651 | Pharmaceutical composition |
Nov 07, 2017
(Expired) | Abbvie |
| Kaletra |
US6521651 (Pediatric) | Pharmaceutical composition |
May 07, 2018
(Expired) | Abbvie |
| Kaletra | US6703403 | Method for improving pharmacokinetics |
Jun 26, 2016
(Expired) | Abbvie |
| Kaletra |
US6703403 (Pediatric) | Method for improving pharmacokinetics |
Dec 26, 2016
(Expired) | Abbvie |
| Kaletra | US6911214 | Flavoring systems for pharmaceutical compositions and methods of making such compositions |
Nov 28, 2021
(Expired) | Abbvie |
| Kaletra |
US6911214 (Pediatric) | Flavoring systems for pharmaceutical compositions and methods of making such compositions |
May 28, 2022
(Expired) | Abbvie |
| Kaletra | US7141593 | Pharmaceutical formulations |
May 22, 2020
(Expired) | Abbvie |
| Kaletra |
US7141593 (Pediatric) | Pharmaceutical formulations |
Nov 22, 2020
(Expired) | Abbvie |
| Kaletra | US7148359 | Polymorph of a pharmaceutical |
Jul 19, 2019
(Expired) | Abbvie |
| Kaletra |
US7148359 (Pediatric) | Polymorph of a pharmaceutical |
Jan 19, 2020
(Expired) | Abbvie |
| Kaletra | US7364752 | Solid dispersion pharamaceutical formulations |
Nov 10, 2020
(Expired) | Abbvie |
| Kaletra |
US7364752 (Pediatric) | Solid dispersion pharamaceutical formulations |
May 10, 2021
(Expired) | Abbvie |
| Kaletra | US7432294 | Pharmaceutical formulations |
May 22, 2020
(Expired) | Abbvie |
| Kaletra |
US7432294 (Pediatric) | Pharmaceutical formulations |
Nov 22, 2020
(Expired) | Abbvie |
| Kaletra | US8025899 | Solid pharmaceutical dosage form | Dec 14, 2027 | Abbvie |
| Kaletra |
US8025899 (Pediatric) | Solid pharmaceutical dosage form | Jun 14, 2028 | Abbvie |
| Kaletra | US8268349 | Solid pharmaceutical dosage form |
Aug 25, 2024
(Expired) | Abbvie |
| Kaletra |
US8268349 (Pediatric) | Solid pharmaceutical dosage form | Feb 25, 2025 | Abbvie |
| Kaletra | US8309613 | Solid pharmaceutical dosage form | Dec 24, 2024 | Abbvie |
| Kaletra |
US8309613 (Pediatric) | Solid pharmaceutical dosage form | Jun 24, 2025 | Abbvie |
| Kaletra | US8377952 | Solid pharmaceutical dosage formulation | Oct 22, 2027 | Abbvie |
| Kaletra |
US8377952 (Pediatric) | Solid pharmaceutical dosage formulation | Apr 22, 2028 | Abbvie |
| Kaletra | US8399015 | Solid pharmaceutical dosage form |
Aug 25, 2024
(Expired) | Abbvie |
| Kaletra |
US8399015 (Pediatric) | Solid pharmaceutical dosage form | Feb 25, 2025 | Abbvie |
| Kaletra | US8470347 | Self-emulsifying active substance formulation and use of this formulation | Sep 17, 2026 | Abbvie |
| Kaletra |
US8470347 (Pediatric) | Self-emulsifying active substance formulation and use of this formulation | Mar 17, 2027 | Abbvie |
| Kaletra | US8501219 | Flavoring systems for pharmaceutical compositions and methods of making such compositions |
Nov 28, 2021
(Expired) | Abbvie |
| Kaletra | US8691878 | Solid pharmaceutical dosage form |
Aug 25, 2024
(Expired) | Abbvie |
| Kaletra |
US8691878 (Pediatric) | Solid pharmaceutical dosage form | Feb 25, 2025 | Abbvie |
Explore Our Curated Drug Screens
Lopinavir; Ritonavir Generics
Several generic applications have been filed for Lopinavir; Ritonavir. The first generic version for Lopinavir; Ritonavir was by Lannett Co Inc and was approved on Dec 27, 2016. And the latest generic version is by Macleods Pharmaceuticals Ltd and was approved on Jul 25, 2024.
Given below is the list of companies who have filed for Lopinavir; Ritonavir generic.
1. HETERO LABS LTD III
Hetero Labs Ltd Unit Iii has filed for 2 different strengths of generic version for Lopinavir; Ritonavir. All of these versions come by the name LOPINAVIR AND RITONAVIR. Given below are the details of the strengths of this generic introduced by Hetero Labs Ltd Iii.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG; 25MG | tablet | Prescription | ORAL | AB | Jun 4, 2021 |
| 200MG; 50MG | tablet | Prescription | ORAL | AB | Jun 4, 2021 |
2. LANNETT CO INC
Lannett Co Inc has filed for 1 generic for Lopinavir; Ritonavir. This 80mg/ml;20mg/ml version comes by the name LOPINAVIR AND RITONAVIR. Given below are the details of the strengths of this generic introduced by Lannett Co Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 80MG/ML; 20MG/ML | solution | Prescription | ORAL | AA | Dec 27, 2016 |
3. LAURUS
Laurus Labs Ltd has filed for 2 different strengths of generic version for Lopinavir; Ritonavir. All of these versions come by the name LOPINAVIR AND RITONAVIR. Given below are the details of the strengths of this generic introduced by Laurus.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 200MG; 50MG | tablet | Prescription | ORAL | AB | Mar 21, 2022 |
| 100MG; 25MG | tablet | Prescription | ORAL | AB | Mar 21, 2022 |
4. MACLEODS PHARMS LTD
Macleods Pharmaceuticals Ltd has filed for 2 different strengths of generic version for Lopinavir; Ritonavir. All of these versions come by the name LOPINAVIR AND RITONAVIR. Given below are the details of the strengths of this generic introduced by Macleods Pharms Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG; 25MG | tablet | Prescription | ORAL | AB | Jul 25, 2024 |
| 200MG; 50MG | tablet | Prescription | ORAL | AB | Jul 25, 2024 |
5. MYLAN LABS LTD
Mylan Laboratories Ltd has filed for 2 different strengths of generic version for Lopinavir; Ritonavir. All of these versions come by the name LOPINAVIR AND RITONAVIR. Given below are the details of the strengths of this generic introduced by Mylan Labs Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG; 25MG | tablet | Prescription | ORAL | AB | Feb 7, 2024 |
| 200MG; 50MG | tablet | Prescription | ORAL | AB | Feb 7, 2024 |